Merus NV (FRA:2GH)
€ 48.8 1.4 (2.95%) Market Cap: 3.27 Bil Enterprise Value: 2.97 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 57/100

Merus NV at Citi BioPharma Conference Transcript

Sep 07, 2023 / 06:40PM GMT
Release Date Price: €21.2
Yigal Nochomovitz
Citigroup Inc. - Moderator

So second to last session of the day, I got [Yamaha Tarvitz] That's one of the biotech analysts here at Citi. It's my pleasure to have with me the CEO of Merus, Bill Lundberg. Bill, thank you for doing this. Appreciate it.

Yeah. Let's -- maybe we can just start with a high-level overview of the platform and what are the key programs. And then we can go program by program after that.

Bill Lundberg
Merus NV - President, CEO & Executive Director

Well, first, thanks, Yigal. I appreciate the continued support from you and Citi and your entire team. Really appreciate all the support and help you've provided Merus recently and also over the years. Merus is a clinical-stage company with multiple clinical stage assets, several of which are already showing really encouraging data to date.

We are focused on bispecific antibodies in oncology, multi-specific antibodies in oncology. The age of the bispecific antibody is really here now. With around 10 approved products and multiple others nearing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot